OncoMatch/Clinical Trials/NCT06744920
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Is NCT06744920 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Remibrutinib (Blinded) and Remibrutinib (Open Label) for generalized myasthenia gravis.
Treatment: Remibrutinib (Blinded) · Remibrutinib (Open Label) — A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage MGFA CLASS II, MGFA CLASS III, MGFA CLASS IV (MGFA)
Confirmed diagnosis of Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG at screening
Prior therapy
Must have received: standard-of-care treatment
Participants who have been on a stable dose of standard-of-care treatment as specified in the protocol
Cannot have received: intravenous immunoglobulin
treated with intravenous immunoglobulins ... in the past month
Cannot have received: plasma exchange
treated with ... plasma exchange (IVIg/PLEX) in the past month
Cannot have received: anti-CD20 antibody (rituximab)
treated with ... rituximab in the past 6 months
Cannot have received: C5 complement inhibitor (eculizumab)
treated with ... eculizumab in the past 2 months
Cannot have received: C5 complement inhibitor (ravulizumab)
treated with ... ravulizumab or other complement inhibitors in the past 3 months
Cannot have received: complement inhibitor
treated with ... other complement inhibitors in the past 3 months
Cannot have received: anti-FcRn therapy (efgartigimod)
treated with ... efgartigimod or other anti-FcRn therapies in the past 3 months
Cannot have received: anti-FcRn therapy
treated with ... other anti-FcRn therapies in the past 3 months
Cannot have received: surgery
had a thymectomy in the past 6 months or a planned thymectomy during the trial period
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Neuromuscular Research Center · Phoenix, Arizona
- Honor Health Research Institute · Scottsdale, Arizona
- Fullerton Neuro and Headache Ctr · Fullerton, California
- University Of Southern California · Los Angeles, California
- Univ Cali Irvine ALS Neuromuscular · Orange, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify